Nuvation Bio Inc. NUVB revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Nuvation Bio Inc. reported revenue across 3 products and services; the largest, License, was $38.2M (+385.7% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- License$38.2Mshare n/a+385.7% yoy
- Product Revenue$24.7Mshare n/ano prior
- Product$24.7Mshare n/ano prior
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Japan$28.8M45.8%+957.6% yoy
- United States$24.7M39.2%no prior
- China$9.41M15.0%+82.8% yoy
Members sum to the consolidated $62.9M for this period.
- License$64.7Mshare n/a+1998.5% yoy
- Product$18.5Mshare n/ano prior
- Product Revenue$18.5Mshare n/ano prior
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.